ArticleScientific reports2018
Longitudinal outcomes of amyloid positive versus negative amnestic mild cognitive impairments: a three-year longitudinal study.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Trial
- Amyloid PET predicts longitudinal functional and cognitive trajectories in a heterogeneous cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Brain MRI volumetry and atrophy rating scales as predictors of amyloid status and eligibility for anti-amyloid treatment in a real-world memory clinic setting.Journal of neurology · 2024Article
- Alzheimer's disease: a review on the current trends of the effective diagnosis and therapeutics.Frontiers in aging neuroscience · 2024Review
- Distinct changes in brain metabolism in patients with dementia and hearing loss.Brain and behavior · 2024Article
- Comparison BetweenJournal of clinical neurology (Seoul, Korea) · 2023Article
- Introducing a gatekeeping system for amyloid status assessment in mild cognitive impairment.European journal of nuclear medicine and molecular imaging · 2022Article
- Gender-specific relationship between thigh muscle and fat mass and brain amyloid-β positivity.Alzheimer's research & therapy · 2022Article
- The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment.Alzheimer's research & therapy · 2022Article
- A Single Baseline Amyloid Positron Emission Tomography Could Be Sufficient for Predicting Alzheimer's Disease Conversion in Mild Cognitive Impairment.Psychiatry investigation · 2022Article
- Independent effect of body mass index variation on amyloid-β positivity.Frontiers in aging neuroscience · 2022Article
- Sex Modulates the Pathological Aging Effect on Caudate Functional Connectivity in Mild Cognitive Impairment.Frontiers in psychiatry · 2022Article
- Different Profiles of Spatial Navigation Deficits In Alzheimer's Disease Biomarker-Positive Versus Biomarker-Negative Older Adults With Amnestic Mild Cognitive Impairment.Frontiers in aging neuroscience · 2022Article
- Cognitive decline according to amyloid uptake in patients with poststroke cognitive impairment.Medicine · 2021Observational
- Relationship between Hearing Loss and Dementia Differs According to the Underlying Mechanism.Journal of clinical neurology (Seoul, Korea) · 2021Article
- Cognitive trajectories of patients with focal ß-amyloid deposition.Alzheimer's research & therapy · 2021Article
- Disease progression modelling from preclinical Alzheimer's disease (AD) to AD dementia.Scientific reports · 2021Article
- Downregulated Platelet miR-1233-5p in Patients with Alzheimer's Pathologic Change with Mild Cognitive Impairment is Associated with Aβ-Induced Platelet Activation via P-Selectin.Journal of clinical medicine · 2020Article
- Distinct Neural Correlates of Executive Function by Amyloid Positivity and Associations with Clinical Progression in Mild Cognitive Impairment.Yonsei medical journal · 2019Article
- Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers.NeuroImage. Clinical · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to compare the longitudinal outcome of amnestic mild cognitive impairment (aMCI) patients with significant Pittsburgh Compound B uptake [PiB(+) aMCI] and those without [PiB(-) aMCI]. Cerebral β-amyloid was measured in 47 patients with aMCI using PiB-positron emission tomography (PET) (31 PiB(+) aMCI and 16 PiB(-) aMCI). Clinical (N = 47) and neuropsychological follow-up (N = 37), and follow-up with brain magnetic resonance imaging (N = 38) and PiB-PET (N = 30) were performed for three years. PiB(+) aMCI had a higher risk of progression to dementia (hazard ratio = 3.74, 95% CI = 1.21-11.58) and faster rate of cortical thinning in the bilateral precuneus and right medial and lateral temporal cortices compared to PiB(-) aMCI. Among six PiB(-) aMCI patients who had regional PiB uptake ratio >1.5 in the posterior cingulate cortex (PCC), three (50.0%) progressed to dementia, and two of them had global PiB uptake ratio >1.5 at the follow-up PiB-PET. Our findings suggest that amyloid imaging is important for predicting the prognosis of aMCI patients, and that it is necessary to pay more attention to PiB(-) aMCI with increased regional PiB uptake in the PCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.